for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

EMA says benefits of Celltrion's COVID-19 antibody drug inconclusive, real-time review on

March 26 (Reuters) - Europe’s drug regulator said on Friday it had finished reviewing South Korean drugmaker Celltrion’s COVID-19 antibody treatment, and found that while it may lower hospitalisation rates, it could not reach a conclusion on its benefits.

However, the treatment, regdanvimab, can be considered for treating patients at high risk of getting severely ill, the European Medicines Agency said, adding that a rolling review of the treatment for European authorisation is still ongoing.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up